Insight Molecular Diagnostics Inc. — Director's Dealing 2025

Mar 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2025-03-26

Reporting Person: Liu James Yang (VP ACCT, Cntlr, Treasurer, PAO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-26	Option to Purchase Common Stock	$3.18	A	10000	Acquired	2035-03-26	Common Stock (10000)	Direct
2025-03-26	Restricted Stock Units	$0	A	18867	Acquired		Common Stock (18867)	Direct

Footnotes

F1: 33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.

F2: 33 and 1/3% of the restricted stock units will vest on each of the one-, two- and three-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date.